Vilazodone hydrochloride, a combined SSRI and 5-HT1A receptor agonist for major depressive disorder

Consultant Pharmacist

Volumn 27, Issue 12, 2012, Pages 857-867

  Guay, David R P ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HEALTHPARTNERS INSTITUTE   (United States)

Author keywords

Depresson; Major depressive disorder; S elective serotonin reuptake inhibitor; Serotonin; Vilazodone

Indexed keywords

PANTOPRAZOLE; PLACEBO; SB 659746 A; UNCLASSIFIED DRUG; VILAZODONE;

ANORGASMIA; AREA UNDER THE CURVE; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG INDUSTRY; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; HEADACHE; HUMAN; INSOMNIA; LETHARGY; LIBIDO DISORDER; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTTRAUMATIC STRESS DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL DYSFUNCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ANIMALS; ANTIDEPRESSIVE AGENTS; BENZOFURANS; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; DRUG INTERACTIONS; HUMANS; INDOLES; PIPERAZINES; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 84872321213     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2012.857     Document Type: Review

References (21)

1. 1A partial agonist for the treatment of depression. I Drugs 2007;10:193-201.
2. VIIBRYD® (vilazodone hydrochloride) tablets prescribing information. new Haven, CT: Trovis Pharmaceuticals; January 2011.
3. 1Aagonists and 5-HT re-uptake inhibitors by combination of indole-butyl-amine and chromenonyl-piperazine structural elements in a single molecular entity. Bioorg Med Chem 2004;12:4843-52.
4. 1A receptor partial agonist. J Pharmacol Expt Ther 2002;302:1220-8.
5. Bartoszyk GD, Hegenbart R, Ziegler H. EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties. Eur J Pharmacol 1997;322:147-53. (Pubitemid 27122887)
6. Treit D, Degroot A, Kashluba S et al. Systemic EMD 68843 injections reduce anxiety in the shock-probe, but not the Plusmaze test. Eur J Pharmacol 2001;414:245-8. (Pubitemid 32181892)
7. A receptor agonist, on anxiety induced by predator stress in rats. Eur J Pharmacol 2004;504:65-77.
8. 1A agonist EMD 68843 on the sleep EEG in healthy men. Psychopharmacology 2001;155:187-92.
9. Heinrich T, Bottcher H. A new synthesis of indole-5-carboxylic acids and 6-hydroxy-indole-5-carboxylic acids in the preparation of an o-hydroxylated metabolite of vilazodone. Bioorg Med Chem Lett 2004;14:2681-4. (Pubitemid 38519073)
10. Hewitt NJ, Buhring K-U, Dasenbrock J et al. Studies comparing in vivo:in vitro metabolism of the pharmaceutical compounds in rat, dog, monkey, and human using cryopreserved hepatocytes, microsomes, and collagen gel immobilized hepatocyte cultures. Drug Metab Dispos 2001;29:1042-50. (Pubitemid 32605921)
11. Khan A. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Exp Opin Invest Drugs 2009;18:1753-64.
12. Rickels K, Athanasiou M, Robinson DS et al. Evidence for the efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:326-33.
13. Khan A, Cutler AJ, Kajdasz DK et al. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry 2011;72:441-7.
14. Robinson D, Kajdasz D, Gallipoli S et al. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmacol 2011;31:643-6.
15. Laughren TP, Gobburu J, Temple RJ et al. Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. J Clin Psychiatry 2011;72:1166-73.
16. Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 2003;53:193-203. (Pubitemid 36135929)
17. Bielski RJ, Cunningham L, Horrigan JP et al. Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study. J Clin Psychiatry 2008;69:571-7. (Pubitemid 351792331)
18. Gammons RE, Stringfellow JC, Hviz AJ et al. Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms: a meta-analysis of eight randomized, controlled studies. Neuropsychobiology 1992;25:193-201.
19. Robinson DS, Rickels K, Feighner J et al. Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacology 1990;10 (3 suppl):67S-76S. (Pubitemid 20212933)
20. Whale R, Terao T, Cowen P et al. Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review. J Psychopharmacology 2010;24:513-20.
21. Rausch JL, Johnson ME, Kasik KE et al. Temperature regulation in depression: functional 5HT1A receptor adaptation differentiates antidepressant response. Neuropsychopharmacology 2006;31:2274-80. (Pubitemid 44413207)